Search clinical trials for: NBI-921352

Total 2489 results

University Hospital, Ghent

Completed

Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery. (SeqB vs SIB)

Radiotherapy After Breast Conserving Surgery

Belgium
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Hepatitis C Virus Infection

United States
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
McGill University Health Centre/Research Institute...

Not yet recruiting

Prospective Evaluation of Gastrointestinal and Genitourinary Side Effects of Pelvic Radiotherapy (PROs)

Radiotherapy Side Effects
Johns Hopkins University

Completed

Computer Delivered and Community Health Worker Supported Smoking Cessation Intervention

Tobacco Smoking

United States
VBI Vaccines Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Coronavirus Infections | COVID-19

Canada
Cairo University

Enrolling by invitation

Cross-cultural Adaptation and Validation of Arabic Version of COMI in Patients With Chronic Neck Pain

Chronic Neck Pain

Egypt
NYU Langone Health

Completed

MMEPT for Traumatic Brain Injury

Traumatic Brain Injury

United States
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
Capital Medical University
Shanghai 10th People's Hospital; Second Affiliated Hospital of Nanchang University and other collaborators

Completed

Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)

Stroke, Acute | Neuroprotection

China
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Pyramid Biosciences

Not yet recruiting

A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors

Solid Tumor

United States
Howard S. Hochster, MD

Recruiting

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Stage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon Carcinoma

United States
University of Alabama at Birmingham

Completed

A Health and Wellness Lifestyle Program to Support Community-Dwelling Persons With Traumatic Brain Injury (POWERS-TBI)

Traumatic Brain Injury

United States
VBI Vaccines Inc.

Withdrawn

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant

Coronavirus Infections | COVID-19

Canada
University of Minnesota

Completed

Mitigating the Impact of Shoulder Movement Dysfunction; a Randomized Controlled Trial

Shoulder Injuries | Shoulder Pain

United States
Democritus University of Thrace

Completed

Impact of Personality on Satisfaction Following Presbyopic Correction

Presbyopia | Patient Satisfaction | Personality

Greece
Wuhan Union Hospital, China

Completed

Retrospective Evaluation to Compare AKE-1 (Navicam SB) Capsule Endoscope System and PillCam SB3 Capsule System

Retrospective Study

China
VA Office of Research and Development

Completed

Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy (PATRIOT)

Diabetes | Foot Ulcer

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan
M.D. Anderson Cancer Center

Active, not recruiting

Tc99m Sestamibi Molecular Breast Imaging

Breast Cancer

United States
Pardes Biosciences, Inc.

Completed

Study of PBI-0451 in Healthy Subjects.

Covid19

New Zealand
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Istanbul Training and Research Hospital

Completed

Effects of Autologous Blood Injection Versus Platelet Rich Plasma on Chronic Plantar Fasciitis (PF:AutovsPRP)

Plantar Fascitis

Turkey
H. Lee Moffitt Cancer Center and Research Institute

Completed

Evaluating Biobanking Educational Tools

Neoplasm

United States
Rush University Medical Center

Completed

Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology

Depression | Anxiety

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Randomized Controlled Trial (RCT) of a Motivational Decision Support System (RCTEDSS)

Schizophrenia

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
University of Nottingham

Completed

HI-Light Pilot Trial for Vitiligo: Hand Held NB-UVB for Early or Focal Vitiligo at Home (HI-Light)

Vitiligo

United Kingdom
University of Pittsburgh
National Institute of Mental Health (NIMH)

Recruiting

Brain, Emotions, and Mind-Wandering (BEAM)

Mood Disorders

United States
Kırıkkale University

Completed

Synbiotic as an Adjunct to Mechanical Treatment of Gingivitis

Smoking | Gingivitis; Chronic
H. Lee Moffitt Cancer Center and Research Institute
Patient-Centered Outcomes Research Institute

Completed

Navigator Guided e-Psychoeducational Intervention

Prostate Cancer

United States
Azienda Ospedaliero-Universitaria Careggi

Completed

Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation

Breast Cancer
Eleven Biotherapeutics

Unknown

Study of EBI-005 in Dry Eye Disease (DED) (EBI-005)

Dry Eye

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Neoplasms

Spain, United States, United Kingdom

3

Subscribe